Disc Medicine holder to sell 2,339 shares, $187K

Disc Medicine, Inc. (IRON) received a notice that Atlas Venture Opportunity Fund II plans to sell common stock under Rule 144.

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) received a notice that Atlas Venture Opportunity Fund II plans to sell common stock under Rule 144. The notice covers 2,339 shares of common stock, with an aggregate market value of $187,236.95, to be sold through Merrill Lynch on or after September 3, 2026 on Nasdaq. Disc Medicine had 38,392,844 shares of common stock outstanding as of the same date; this is a baseline figure, not the amount being sold. The shares to be sold were originally acquired in a private placement on May 1, 2020 for cash.

Key Figures

Shares to be sold under Rule 144: 2,339 shares Aggregate market value of shares to be sold: $187,236.95 Shares outstanding: 38,392,844 shares +2 more

5 metrics

Shares to be sold under Rule 144 2,339 shares Common stock of Disc Medicine, Inc. covered by the Form 144 notice

Aggregate market value of shares to be sold $187,236.95 Reported value for the 2,339 Disc Medicine, Inc. shares in the planned sale

Shares outstanding 38,392,844 shares Disc Medicine, Inc. common stock outstanding as of September 3, 2026

Planned sale date September 3, 2026 Date associated with the proposed Nasdaq sale of the shares

Acquisition date of securities May 1, 2020 Date the shares were acquired in a private placement for cash

Key Terms

Rule 144, Private Placement, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Private Placement financial

"Common Stock | 05/01/2020 | Private Placement | Issuer"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

aggregate market value financial

"Common Stock | Merrill Lynch ... | 2339 | 187236.95 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing report for Disc Medicine, Inc. (IRON)?

It reports that Atlas Venture Opportunity Fund II plans to sell 2,339 shares of Disc Medicine, Inc. common stock under Rule 144, with an aggregate market value of $187,236.95, through Merrill Lynch on or after September 3, 2026 on Nasdaq.

How many Disc Medicine (IRON) shares are covered by this planned Rule 144 sale?

The notice covers 2,339 shares of Disc Medicine, Inc. common stock. These shares are proposed to be sold under Rule 144 through Merrill Lynch and were originally acquired in a private placement on May 1, 2020 for cash.

What is the aggregate market value of the Disc Medicine (IRON) shares in the Form 144?

The planned sale involves an aggregate market value of $187,236.95 for the 2,339 shares of Disc Medicine, Inc. common stock to be sold under Rule 144. This value is reported in connection with the proposed brokerage transactions through Merrill Lynch.

How many Disc Medicine (IRON) shares were outstanding at the time of this Form 144 notice?

Disc Medicine, Inc. had 38,392,844 shares of common stock outstanding as of September 3, 2026. This number provides context for the company’s capital structure and is not the amount being sold under the Form 144 notice.

How and when were the Disc Medicine (IRON) shares being sold under this Form 144 originally acquired?

The 2,339 shares of Disc Medicine, Inc. common stock were originally acquired by the selling holder in a private placement from the issuer on May 1, 2020 for cash, as stated in the securities acquisition section of the notice.

Which broker is named for the planned sale of Disc Medicine (IRON) shares in this Form 144?

The notice lists Merrill Lynch, located at One Bryant Park in New York, as the broker for the planned sale of 2,339 shares of Disc Medicine, Inc. common stock under Rule 144 on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:37 PM Accepted by SEC EDGAR 09/03/2026 - 05:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001885327
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Disc Medicine, Inc.
SEC File Number	001-39438
Address of Issuer	321 ARSENAL STREET, SUITE 101 WATERTOWN MASSACHUSETTS 02472
Phone	617-674-9274
Name of Person for Whose Account the Securities are To Be Sold	Atlas Venture Opportunity Fund II, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	2339	187236.95	38392844	09/03/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			2339	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	See attached Table II for sales of securities over the last three months.
Date of Notice	09/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ommer Chohan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)